The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...
The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has accelerated approval as a second-line treatment for HER2-mutated NSCLC and is dosed ...
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.
Malaysia's IHH Healthcare said on Thursday its unit is seeking compensation of up to 109.3 billion rupees ($1.25 billion) from Japan's Daiichi Sankyo for its stake buy in India's Fortis Healthcare.
The company’s PATHWAY HER2 antibody test—used to help screen patients for treatment with Enhertu (trastuzumab deruxtecan-nxki), the antibody-drug conjugate jointly developed by Daiichi Sankyo ...
Approval of Enhertu was granted to AstraZeneca and Daiichi Sankyo. More Information ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results